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Chapter1 
Ubiquitin-dependent and -independent  
degradation of p35 
  
 2 
Summary 
 
Cdk5 is a versatile protein kinase that is involved in various neuronal activities, such as 
the migration of newborn neurons, neurite outgrowth, synaptic regulation and 
neurodegenerative diseases. Cdk5 requires the p35 regulatory subunit for activation. 
Because Cdk5 is more abundantly expressed in neurons compared to p35, the p35 
protein levels determine the kinase activity of Cdk5. P35 is a protein with a short 
half-life that is degraded by proteasomes. While ubiquitination of p35 has been 
previously reported, the degradation mechanism of p35 is not yet known. Here, I 
intended to identify the ubiquitination site(s) in p35. Because p35 is myristoylated at the 
N-terminal glycine, the possible ubiquitination sites are the lysine residues in p35. I 
mutated all 23 Lys residues to Arg (p35 23R), but p35 23R was still rapidly degraded 
by proteasomes. The degradation of p35 23R in primary neurons and the Cdk5 
activation ability of p35 23R suggested the occurrence of ubiquitin-independent 
degradation of p35 in physiological conditions. I found that p35 has the amino acid 
sequence similar to the ubiquitin-independent degron in the NKX3.1 homeodomain 
transcription factor. An Ala mutation at Pro247 in the degron-like sequence made p35 
23R stable. These results suggest that p35 can be degraded by two degradation 
pathways: ubiquitin-dependent and ubiquitin-independent. The rapid degradation of p35 
by two different methods would be a mechanism to suppress the production of p25, 
which over-activates Cdk5 to induce neuronal cell death.   
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Introduction 
 
Cyclin-dependent kinases (Cdks) are a family of Ser/Thr kinases that are activated by 
binding a regulatory subunit called cyclin. Most members of Cdks are expressed in 
proliferating cells to promote cell cycle progression (Mulumbres et al, 2014). Cdk is a 
catalytic subunit, which is activated by an activation subunit called cyclin. Different 
from other cdks, Cdk5 is activated by p35 or p39 non-cyclin proteins, which are mainly 
expressed in post-mitotic neurons (Figure 1) (Figure 2) (Hisanaga et al., 2010). Cdk5 is 
a versatile kinase that is involved in many neuronal activities, including neuronal cell 
layer formation, synaptic transmission, membrane trafficking and neuron cell death 
(Shah et al., 2014). P35 and p39 appear to share common and/or distinct functions for 
Cdk5, with p35 being the predominant activator. This is shown by the phenotypes of 
knockout (KO) mice; p35 KO mice display abnormal neural layers in the cerebral 
cortex (Chae et al., 1997), and p39 KO mice do not show apparent abnormalities, 
whereas p35 and p39 double KO mice are perinatal lethal with abnormal neural layers, 
as are the Cdk5 KO mice (Ohshima et al. 1996, Gilmore et al. 1998, Ko et al. 2001). 
Indeed, p35 is the major activator of Cdk5. Therefore, I thought the regulation of the 
protein amount of p35 is critical for the Cdk5 activity. To understand the precise 
function of Cdk5-p35 in various neuronal activities, it is important to reveal the 
regulation mechanism of Cdk5 activity.  
    As well as being cell cycle Cdks, Cdk5 is a stable protein and is expressed more 
abundantly than p35 in neurons (Lee et al. 1996, Zhu et al. 2005). Therefore, Cdk5 
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activity is determined primarily by the available amount of activator protein p35, and 
the protein amounts of p35 are regulated by the balance between synthesis and 
degradation (Hisanaga et al. 2010)(Figure 2). While the synthesis of p35 is stimulated 
by NGF or BDNF (Tokuoka et al., 2001; Harada et al., 2001; Bogush et al. 2007), the 
degradation of p35 is carried out by proteasomes (Patrick et al., 1998; Saito et al. 1998). 
The degradation is a major determinant of the p35 level, which is reduced by treating 
neurons with excitatory neurotransmitter glutamate (Wei et al. 2005). P35 associates 
with membranes via myristoylation at the N-terminal glycine (Patrick et al., 1999; 
Asada et al., 2008), and this association enhances the degradation of p35 (Minegishi et 
al. 2010). On the other hand, p35 is cleaved by a calcium-dependent protease calpain to 
produce the C-terminal stable fragment p25 (Patrick et al., 1999; Kusagawa et al., 2000; 
Lee et al., 2000). Although the physiological function of Cdk5-p25 has been recently 
reported (Engmann et al., 2011; Rei et al., 2015), its abundance induces neuronal cell 
death in neurodegenerative diseases (Figure 3) (Cruz et al., 2004). Rapid turnover of 
p35 is suggested to be a mechanism to prevent p25 production (Hisanaga et al., 2010). 
Therefore, it is particularly important to determine the degradation mechanism of p35. 
Interestingly, the addition of the N-terminal hepta-peptide containing the myristoylation 
site of p35 facilitates p35 lability (Minegishi et al., 2010), indicating that the 
degradation of p35 occurs selectively on membranes (Figure 4). While p35 previously 
been demonstrated to be post-translationally modified by ubiquitination (Patrick et al. 
1998), the responsible E3 ligase has not been identified yet in the neuron, and its 
degradation pathway is not completely understood.     
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     The ubiquitin-proteasome system is a major component of the proteolytic 
machinery that performs the degradation of proteins in cells (Hershko et al., 1992; 
Ravid et al., 2008). The proteasome is a large complex of multi-catalytic proteases that 
degrade proteins to small peptides. There are several types of proteasome. The 26S 
proteasome is a complex of 20S proteasome and 19S particles. The 20S proteasome is 
the core of the proteasome, and 19S is a regulatory particle (PA700) that recognizes and 
unfolds ubiquitinated proteins. The unfolded proteins are proteolyzed by being inserted 
into the 20S chamber. Ubiquitination is a critical step in the ubiquitin-proteasome 
system for selective degradation. Ubiquitin is a small protein that is tagged to substrate 
proteins to be degraded.  
Conjugation of ubiquitin to substrate proteins is complicated processes, which 
are carried out by three enzymes called E1, E2 and E3. E1 activates ubiquitin. E2 is a 
ubiquitin conjugating protein, and E3 is ubiquitin ligase (Figure 5). Poly-ubiquitination 
through Lysine 48 is a signal for proteasomal degradation of substrate proteins. 
Poly-ubiquitination through lysine 63 is involved in DNA repair or trafficking of 
membrane proteins (Figure 6). There are large numbers of E3 ligases recognize and 
conjugate ubiquitin for specific substrate (Tanaka et al., 2004). E3 ligases are classified 
into two types, ring finger type and HECT type. There are larger numbers of ring finger 
types than HECT types. For examples, MDM2, c-Cbl, and Parkin are ring finger types. 
There are several tens of HECT types E3 ligases including Nedd4, and Smurf. The E3 
ligase for p35 has not been found in the brain, although in pancreatic β-cells, Pja2 has 
been recently reported to have E3 ligase activity to p35 (Sakamaki et al., 2014). 
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     However, poly-ubiquitination is not an absolute requirement for proteasomal 
degradation. Ornithine decarboxylase is a well-known example of 
ubiquitin-independent proteasomal degradation (Murakami et al., 2000; Hoyt et al., 
2003). The numbers of proteins susceptible to ubiquitin-independent proteasomal 
degradation have recently been increasing. They include thymidylate synthase, Rpn4, 
p21 Cdk inhibitor, p53 tumor suppressor, c-Fos, tau, α-syn, myoglobin, Nkx3.1, Pih1, 
and so on (Peña et al., 2006; Peña et al., 2009; Ha et al., 2012; Chen et al., 2004; 
Tavekov et al., 2010; Basbous et al., 2008; Gun et al., 2010; Tofaris et al., 2001; 
Singh-Gautam et al., 2012; Rao et al., 2012; Paci et al., 2016). Degron sequences 
recognized by proteasomes have been investigated in these proteins. For example, the 
unfolding regions of the proteins are recognized as ubiquitin-independent proteasomal 
degradation site. Rpn4, p21, p53, tau, α-syn have this type of the unfolded region. On 
the other hand, myoglobin and Nkx3.1 have a degron sequence on folding region. These 
two types of the degron are regulates differently. This is because the unfolding region 
can enter into proteasome cavity directly, the degron in folding region cannot access 
proteasome. Their regulation mechanisms and physiological meanings are largely 
unknown yet.  
Herein, I intended to identify the ubiquitination sites on p35 for a better 
understanding of its ubiquitin-proteasome-dependent degradation mechanism. 
Unexpectedly, however, I found that non-ubiquitinated p35 was degraded at a 
comparable rate to wild-type p35. Our results indicate that p35 is degraded by 
proteasomes by two pathways: ubiquitin-dependent and ubiquitin-independent.   
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Materials and Methods 
 
Antibodies and Chemicals 
Cycloheximide was purchased from Sigma (St Louise, MO). DMSO (Dimethyl 
sulfoxide) were purchased from WAKO (JAPAN). Anti-p35 (C19) and anti-Cdk5 
(DC17) antibody was obtained from Santa Cruz Biotechnology (Santa Cruz, CA). 
Anti-actin (A2066) and anti- Myc (9E10) antibodies were purchased from Sigma. 
Anti-mice IgG and Anti-Rabbit IgG antibodies were purchased from Dako (Denmark). 
Anti-polyUbiquitin antibody was obtained from NIPPON BIO-TEST 
LABORATORIES INC. (Asaka, Japan). These antibodies were diluted 1000 times by 
TBST (50 mM Tris-Cl pH 7.5, 150 mM NaCl and 0.1% Tween-20) or Can Get Signal 
(TOYOBO, JAPAN) for western blotting.  
 
Cell culture and Transfections 
 Neuro2A cells and HEK293T cells were obtained from JCRB Cell Bank (Osaka, 
Japan). HEK293T cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM, 
Sigma, MO) add 10 percent fatal bovine serum, 100units/ml penicillin, and 0.1 mg/ml 
streptomycin. Neuro2A cell were cultured Minimum Essential Medium (MEM, Thermo 
Fisher) containing 10 percent fetal bovine serum, Non-essential Amino acids (Sigma, 
MO) 100units/ml penicillin, and 0.1mg/ml streptomycin. These cells were cultured at 
37 degrees and 5% carbon dioxide. Hek293T cell and Neuro2A cells were transfected 
expression plasmid using Hilly Max (Dojindo, Kumamoto, Japan) or PolyFect (Qiagen, 
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Valencia, CA) at 24 h after plating.  
 
Construction of Expression Vector 
 p35, Cdk5 expression vector in pCMV5 were reported in previously (Minegishi, 2010). 
Lys-to-Arg mutants were constructed by polymerase chain reaction (PCR) with Pfu 
Ultra DNA polymerase  (Agilent Technologies, Santa Clara, CA) or EX Taq (Takara, 
Japan) using following primers. 
 p35 K126/127R was amplified by PCR using p35 in pCMV5 as  a template with 5’- 
CTCCTCTTCTGTCAGGAGGGCCCCGCACC-3’ as a forward primer and 5’- 
GGTGCGGGGCCCTCCTGACAGAAGAGGAG-3’ as a Reverse primer. 
 p35 K140R was amplified by PCR using p35 in pCMV5 as template with 5’- 
TGCAGGGACACCCAGACGGGTCATCGTCC-3’ as a forward primer and 5’- 
GGACGATGACCCGTCTGGGTGTCCCTGCA -3’ as a Reverse primer. 
 p35 K167R was amplified by PCR using p35 in pCMV5 as template with 5’- 
GTGCTACCGCCTGAGGCACTTGTCCCCAA-3’ as a forward primer and 5’- 
TTGGGGACAAGTGCCTCAGGCGGTAGCAC-3’ as a Reverse primer. 
 p35 K298/299R was amplified by PCR using p35 in pCMV5 as template with 5’- 
CGGTCAGGAGGACAGGAGGCGACTCCTCCTGG as a forward primer and 5’- 
CCAGGAGGAGTCGCCTCCTGTCCTCCTGACCG-3’ as a Reverse primer. 
 N7-p25 2R was amplified by PCR using N7-p25-myc in pCDNA3 as template. 
Forward and reverse primers were using same as making K126/127R mutant. 
 N7-p25 3R was amplified by PCR using N7-p25 2R as template. Forward and Reverse 
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primer were using same as making K140R mutant. 
 N7-p25 4R was amplified by PCR using N7-p25 3R as a template. Forward and 
Reverse primer were using same as making K167R mutant. 
 N7-p25 5R was amplified by PCR using N7-p25 4R as a template with 5’- 
CTCCTACCCGCTCAGGCCCTTCCTGGTAG-3’ as forward primer and 5’- 
CTACCAGGAAGGGCCTGAGCGGGTAGGAG-3’ as reverse primer.  
 N7-p25 6R was amplified by PCR using N7-p25 5R as a template with 5’- 
GGTAGAGAGCTGTAGGGAAGCCTTTTGGG-3’ as forward primer and 5’- 
CCCAAAAGGCTTCCCTACAGCTCTCTACC-3’ as reverse primer.  
 N7-p25 7R was amplified by PCR using N7-p25 6R as a template with 5’- 
CCTCATGAGCTCCAGGATGCTGCAGATCA-3’ as forward primer and 5’- 
TGATCTGCAGCATCCTGGAGCTCATGAGG-3’ as reverse primer.  
 N7-p25 8R was amplified by PCR using N7-p25 7R as a template with 5’- 
GTTCTCTGACTTGAGGAATGAGAGCGGTC-3’ as forward primer and 5’- 
GACCGCTCTCATTCCTCAAGTCAGAGAAC -3’ as reverse primer. 
 N7-p25 10R was amplified by PCR using N7-p25 8R as a template. Forward and 
reverse primers were using same as making K298/299R mutant. 
 N7-p25 11R was amplified by PCR using N7-p25 10R as a template with 5’- 
GGATCGGGAACAAAGACTCATCTCAGAAG-3’ as forward primer and 5’- 
CTTCTGAGATGAGTCTTTGTTCCCGATCC-3’ as reverse primer. 
 p35 1R was amplified by PCR using p35 in pCMV5 as template as template with 5’- 
CCCCAGCTATCGGAGGGCCACACTGTTTG-3’ as forward primer and 5’- 
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CAAACAGTGTGGCCCTCCGATAGCTGGGG-3’ as reverse primer.  
 p35 2R was amplified by PCR using p35 1R as template as template with 5’- 
CGTGCAGAACAGCAGGAACGCCAAGGACA-3’ as forward primer and 5’- 
TGTCCTTGGCGTTCCTGCTGTTCTGCACG-3’ as reverse primer. 
 p35 3R was amplified by PCR using p35 2R as template as template with 5’- 
CAGCAGGAACGCCAGGGACAAGAACCTGA-3’ as forward primer and 5’- 
TCAGGTTCTTGTCCCTGGCGTTCCTGCTG-3’ as reverse primer. 
 p35 4R was amplified by PCR using p35 3R as template as template with 5’- 
GAACGCCAGGGACAGGAACCTGAAGCGGC-3’ as forward primer and 5’- 
GCCGCTTCAGGTTCCTGTCCCTGGCGTTC-3’ as reverse primer.  
 p35 5R was amplified by PCR using p35 4R as template as template with 5’- 
GGACAGGAACCTGAGGCGGCACTCCATCA-3’ as forward primer and 5’- 
TGATGGAGTGCCGCCTCAGGTTCCTGTCC-3’ as reverse primer.  
 p35 6R was amplified by PCR using p35 5R as template as template with 5’- 
GGTGCTGCCTTGGAGGAGGATCGTGGCGG-3’ as forward primer and 5’- 
CCGCCACGATCCTCCTCCAAGGCAGCACC-3’ as reverse primer. 
 p35 9R was amplified by PCR using p35 6R as template as template with 5’- 
GGTGTCAGCGAGGAGGAGGAACTCCAGGA-3’ as forward primer and 5’- 
TCCTGGAGTTCCTCCTCCTCGCTGACACC-3’ as reverse primer. 
 p35 11R was amplified by PCR using p35 9R as template as template with 5’- 
GAAGAAGAACTCCAGGAGGGCGCAGCCCA-3’ as forward primer and 5’- 
TGGGCTGCGCCCTCCTGGAGTTCTTCTTC-3’ as reverse primer. 
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 p35 13R was amplified by PCR using p35 11R as template as template with 5’- 
CAATGAGAACCTGAGGAGGTCGCTGTCCT-3’ as forward primer and 5’- 
AGGACAGCGACCTCCTCAGGTTCTCATTG- as reverse primer. 
 p35 15R was amplified by PCR using p35 13R as template as template. Forward and 
reverse primers were using same as making K126/127R mutant. 
 p35 16R was amplified by PCR using p35 15R as template as template. Forward and 
reverse primers were using same as making K140R mutant. 
 p35 17R was amplified by PCR using p35 16R as template as template. Forward and 
reverse primers were using same as making K167R mutant. 
 p35 18R was amplified by PCR using p35 17R as template as template. Forward and 
reverse primers were using same as making N7p25 5R mutant. 
 p35 19R was amplified by PCR using p35 18R as template as template. Forward and 
reverse primers were using same as making N7p25 6R mutant. 
 p35 20R was amplified by PCR using p35 19R as template as template. Forward and 
reverse primers were using same as making N7p25 7R mutant. 
 p35 21R was amplified by PCR using p35 20R as template as template. Forward and 
reverse primers were using same as making N7p25 8R mutant. 
 p35 23 R was amplified by PCR using p35 21R as template as template. Forward and 
reverse primers were using same as making N7p25 10R mutant. 
p35 P247A was constructed by PCR using p35 in pCMV5 as a template with 
5’-TACCCGCTCAAGGCCTTCCTGGTAGAGA-3’ as forward primer and 
5’-TCTCTACCAGGAAGGCCTTGAGCGGGTA-3’ as reverse primer. 
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 p35 23R P247A was constructed by PCR using p35 23R in pCMV5 as a template with 
5’-TACCCGCTCAGGGCCTTCCTGGTAGAGA-3’ as forward primer and 
5’-TCTCTACCAGGAAGGCCCTGAGCGGGTA -3’ as reverse primer.  
 p35 tagged with HA expression vector were amplified by PCR using p35 WT or 23R 
in pCMV5 as a template with 5’- GTTAAGCTTATGGGCACGGTGCTGTC as a 
forward primer and 
5’-ACCCGACCTAGCCATGGGTATGCTACAAGGTCTAATGCGAACTCTTAAGA
AT-3’ as a reverse primer. PCR products were digested by HindⅢand EcoRⅠand then 
ligated into pBluescript. After the purification, p35 HA in pBluescript were digested by 
HindⅢ and BamHⅠand then ligated into pCAG-MCS2 at these sites.    
 
DNA Sequencing  
 All of PCR products were confirmed by DNA sequence using Big Dye Terminator ver. 
3.1 and a 3130 genetic analyzer (ThermoFisher Scientific, MO) according to a 
manufactural protocol. HiDi Formamide is also obtained from Thermo Fisher.  
 
Western Blotting Analysis 
I used 12.5 percent polyacrylamide for SDS-PAGE (Sodium dodecyl 
sulfate-polyacrylamide electrophoresis) according to the methods of Laemmli. 
Molecular size markers of protein were used Protein Multi Color 3 (Bio Dynamics 
Laboratory Inc. Japan) or WIDE-VIEW Prestained Protein Size Marker 3. After the 
electrophoresis, separating protein were transferred to Immobilon membranes 
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(Millipore, MA) using semi-dry blotting methods, which used blotting buffer (25mM 
Tris-hydroxylmethylaminomethane, 192mM Glycine, 0.1% SDS, 20% Methanol). After 
blotting, membrane were blocking with 5％ skim milk in TBST. After the blocking, 
membranes were wash TBST at three times. This membrane were incubated and reacted 
with primary antibody in 1 hour. After that, the membrane were incubate with 
secondary antibodies, which is conjugated HRP (Horse Radish Peroxidase), then it were 
washed by TBST in three times. After that, the membranes were reacted ECL western 
blotting detection regent (GE healthcare, UK) and detected by X-ray firm (Fuji film, 
Japan) or FUSION XL (Vilber, France).   
 
CHX pulse-chase Assay 
 Cycloheximide was dissolved 50mg/mL by DMSO. When the cells were treated by 
CHX, CHX were diluted 1000 times by culture medium. Final concentration of CHX is 
50µg/ µL. After medium change, the cells were treated indicated time and then the cells 
were collected by PBS. Collected cells were certificated and then remove PBS. After 
that, the cells (ppt) were frozen by Liquid-Nitrogen. Freezing cells were homogenized 
by LSB (Lemmli sampled buffer, 0.25M Tris-Cl, 8%SDS, 40% glycerol, 20% 
2-Mercaptoethanol, 0.01% Bromophenol blue) and then boiled at 5 minutes. Protein 
levels of these samples were calculated by Western Blotting Analysis.  
 
Immunoprecipitation and Kinase Assay 
Neuro2a cells expressing Cdk5 and N7-p25, N7-p25 11R, p35 or p35 23R were 
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collected by PBS and then lysed in 20 mM MOPS at pH 6.8, 1 mM EGTA, 0.1 mM 
EDTA, 0.15 M NaCl, 1 mM MgCl2, 10 µg/ml Leupeptin, 0.4 mM Pefabloc, and 0.3% 
(v/v) Nonidet P-40. After centrifugation (13500rpm, 15 min), anti-Cdk5 (C8) antibody 
were added into supernatant. 1 hour after adding antibody, Protein G sepharose were 
added into the sample. After the immunoprecipitation, the sample were washed by wash 
buffer (20mM MOPS, 1mM EGTA, 0.1mM EDTA, 0.3M NaCl, 1mM MgCl2, 0.5% 
Nonidet P-40). After the washing, buffer were exchanged for activity measurement 
buffer (10mM MOPS, 1mM EGTA, 0.1mM EDTA, 1mM MgCl2). The kinase activity 
of the immunoprecipitates was measures with histone H1 and [γ-32P] ATP as substrates 
of Cdk5. For the polyubiquitination assay, Neuro2a cells expressing N7-p25, p35 or its 
mutants were treated with 20 µM MG132 for 5 h. At the end of the treatment, the cells 
were collected and the cell extracts were incubated with anti-p35 for p35 or anti-myc 
for N7-p25, which was followed by coprecipitation with protein A Sepharose beads.  
 
Statistical Analysis 
All of the statistical treatments were performed by one-way analysis of variance with 
Tukey’s post hoc test.  
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Results 
 
Effect of arginine mutation of the lysine residues in the C-terminal p25 region on the 
stability of p35 or N7-p25   
 p35 has been shown to be degraded by proteasomes through its polyubiquitination 
(Patrick et al., 1999; Minegishi et al., 2010; Sato et al., 2003). To better understand the 
regulation of p35 degradation, a good goal would be to identify the E3 ligase that 
catalyzes its ubiquitination. An approach towards identifying the E3 ligase is to 
determine the ubiquitination sites in p35. Ubiquitin conjugation occurs on the amino 
group of lysine residue(s) or the amino terminal residue of the protein. The α–NH2 
group of the N-terminal glycine of p35 is blocked by myristoylation (Patrick et al., 
1999; Asada et al., 2008; Minegishi et al., 2010). Therefore, as candidates for possible 
ubiquitination sites, I first focused on the lysines at amino acids 126/127, 140 and 167 
because they are relatively close to Thr138, the phosphorylation of which is involved in 
the degradation of p35 (Saito et al., 2003; Kamei. et al., 2007). Also, amino acids 
298/299 in the C-terminal region share homology with double Lys residues that serve as 
ubiquitination sites in p53, a tumor suppressor protein with a short half-life (Rodriguez 
et al., 2000) (Figure 7). I mutated these Lys to Arg and cotransfected the mutant with 
Cdk5 in Neuro2a cells to observe the degradation in the presence of cycloheximide, a 
protein synthesis inhibitor, for 1 and 3 h. However, none of the mutations stabilized p35 
(Figure 8).  
     While p25 is a stable C-terminal fragment of p35 (Patrick et al., 1999; Kusagawa 
 16 
et al., 2000; Lee et al., 2000), the addition of the 7 N-terminal amino acids (N7), 
including the myristoylation motif, confers p25 with susceptibility to proteasomal 
degradation (Minegishi et al., 2010). The results suggest that the ubiquitination site(s) 
are present in the p25 region because there is no lysine in the N7 sequence. Accordingly, 
I mutated the Lys residues in N7-p25 in the order described in Figure 9. I expected that 
N7-p25 would become stable when the critical Lys is replaced with Arg. In this 
experiment, I used N7-p25 with a myc-tag at the C-terminus because I wondered if 
multiple Lys-to-Arg mutations might affect the reactivity of anti-p35 antibodies. 
Mutations at the N-terminal Lys residues at 126, 127, 140 and 167 did not change the 
stability (Figure 10, 0R-4R). Arg mutants of N7-p25 became more labile when Lys 
residues in the C-terminal region were further changed (Figure 10, 5R-7R). Additional 
mutations at Lys at 246, 254 and 271 in the core of the Cdk5 activation domain did not 
further alter the stability (Figure 10, 8R-10R). Although I mutated all of the Lys 
residues in p25, N7-p25 was still unstable. There was a Lys residue in the myc-tag 
EQKLISEEDL. The Lys null version of N7-p25 11R was constructed, and its stability 
was examined. Surprisingly, however, N7-p25 11R was still unstable (Figure 10, 11R).  
     I confirmed that N7-p25 11R was not ubiquitinated (Figure 11). N7-p25 11R was 
cotransfected with HA-ubiquitin into Neuro2a cells. After immunoprecipitation with 
anti-myc, ubiquitination was assessed by immunoblotting with anti-HA or 
anti-polyubiquitin (poly Ub) antibodies. In contrast to the strong ubiquitination of 
N7-p25, it was greatly reduced in N7-p25 11R. Some signal of N7-p25 10R suggested 
ubiquitination at Lys in the myc-tag sequence.  
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     I investigated whether N7-p25 11R would lose its conformation and therefore be 
degraded by proteasomes as a misfolded protein. To test this possibility, N7-p25 11R’s 
ability to bind or activate Cdk5 was compared with that of N7-p25. N7-p25 11R was 
immunoprecipitated with Cdk5 as much as N7-p25 (Figure 12, left). The kinase activity 
of Cdk5 bound to N7-p25 11R was measured with histone H1 phosphorylation. No 
significant difference was observed between Cdk5-N7-p25 and Cdk5-N7-p25 11R 
(Figure 12, right). These results suggest that N7-p25 11R retains the same capacity for 
activating Cdk5 as does N7-p25. 
 
Lys null mutant of p35, p35 23R, is also degraded by proteasomes 
 The above results with N7-p25 raised the possibility that p35 would be degraded 
without ubiquitination. However, there are still 13 additional Lys residues in the 
N-terminal p10 region. To test for the possibility that the Lys residues in the N-terminal 
p10 region provide ubiquitination sites, I constructed a lysine-null mutant of full-length 
p35 (p35 23R), in which all 23 lysine residues of p35 were change to arginine (Figure 
13). Here, I used p35 WT and p35 23R without any tag because the Arg-mutations in 
the C-terminal region of p35 did not affect the immunoreactivity to anti-p35 antibodies 
(C19). Because the N-terminus of p35 is blocked, as described above, p35 23R has no 
ubiquitination sites and, in fact, polyubiquitination was not detected in p35 23R (Figure 
14). I observed the degradation of p35 23R in Neuro2a cells. p35 23R was decreased in 
the presence of CHX, and this decrease was suppressed with the proteasomal inhibitor 
MG132 as well as the more specific proteasome inhibitor Epoxomicin (Figure 15). 
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These results indicate that p35 23R is degraded by proteasomes without ubiquitination. 
I confirmed the proper folding of p35 23R by its binding and activation of Cdk5. p35 
23R was co-immunoprecipitated with anti-Cdk5, and Cdk5-p35 23R displayed histone 
H1 phosphorylation activity as much as Cdk5-p35 WT (Figure 16). 
     Degradation of p35 is affected by phosphorylation at Thr138 (Saito et al. 2003, 
Kamei et al. 2007). Phosphorylation of p35 was assessed by the electrophoretic mobility 
shift in Phos-tag SDS-PAGE. P35 was separated into 3 bands; the intense lowest band 
is unphosphorylated p35, the slightly higher band is Thr138-phosphorylated p35, and 
the upper band is p35 phosphorylated at Thr138 and Ser91 according to our previous 
results (Hosokawa et al. 2010). Co-expression with Cdk5 reduced the mobility of p35 
mainly by phosphorylation at Ser8 (Figure 17). P35 23R showed a similar but not 
identical banding pattern to p35 in the presence or absence of Cdk5, which was 
probably because of the presence of Arg mutations at as many as 23 sites. However, I 
believe that Arg mutations did not affect the phosphorylation at Thr138 because bands 
containing Thr138 phosphorylation were detected. Furthermore, I observed that p35 
23R showed the same cellular localization of p35 by immunofluorescent staining 
(Figure 18). These results suggest that p35 23R retains a conformation that is capable of 
binding and activating Cdk5 as well as that wild-type p35 is degraded by proteasomes 
ubiquitin-independently.  
 
Effect of Cdk5 binding on the degradation of p35 and p35 23R 
When p35 or p35 23R alone was transfected into Neuro2a cells, the expression levels 
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were higher with p35 23R than with p35. In contrast, p35 and p35 23R showed similar 
expression levels when Cdk5 was co-expressed (Figure 19). The results suggest that 
Cdk5 affects the stability of p35 23R and p35 differently, and I examined the effect of 
exogenous co-expression of Cdk5 on the degradation of p35. 
     I measured the degradation rates of p35 and p35 23R in the presence of Cdk5 by 
CHX chase assay. p35 23R showed the same degradation rate as p35, and the p35 and 
p35 23R levels were reduced to approximately 60% in 1 h after CHX addition (Figure 
20). In contrast, in the absence of Cdk5, p35 23R was degraded slower than p35 (Figure 
21). While p35 was decreased to approximately 60% in 1 h, which was as fast as in the 
presence of Cdk5, more than 70% of the p35 23R remained at 3 h after the addition of 
CHX (Figure 21). These results suggest that the degradation of p35 23R is slowed down 
in the absence of Cdk5, whereas the degradation rate of p35 is not affected by the 
expression of Cdk5.  
 
Degradation of p35 23R in primary cortical neurons 
I used Neuro2a cells in the above experiments. Neuro2a is a neuronal cell line that is 
derived from the central nervous system, but these cells are not neurons themselves. To 
validate the physiological relevance of ubiquitin-independent degradation, I examined 
whether p35 23R was degraded as p35 was in neurons. p35 or p35 23R tagged with HA, 
which contains no Lys residues, were constructed and transfected into primary cortical 
neurons at 3 days-in-vitro (3 DIV). Their degradation rates were assessed by the CHX 
chase assay. p35 can be degrade by proteasome (Figure 22). The degradation rates are 
 20 
different between p35 WT and p35 23R. On the other hand, these speeds are same at 
early section of CHX treatment. This result indicated that p35 can be degraded 
independently of ubiquitin by proteasomes in neurons. 
 
Ubiquitin-independent degron sequence in p35 
I investigated how p35 is recognized by proteasomes without ubiquitination. The 
numbers of proteins, which are known to be degraded by proteasomes independent of 
ubiquitin, have increased recently. Among them, I was interested in a 
ubiquitin-independent degron that is found in the C-terminal region of NKX3.1, a tumor 
repressor (Guan et al., 2008). The ubiquitin-independent degron sequence is composed 
of 21 amino acids with a PXL motif in the middle (Rao et al., 2012). P35 has a similar, 
but not identical, sequence in residues 240-258 (Figure 23). Pro221 is a critical amino 
acid for the degron activity. Pro247 on p35 corresponds to Pro221 in the degron of 
NKX3.1. Pro247 are located between α3 and α5 (Figure 24). And side chain of Pro247 
is located in molecular surface of p25 (Figure 25). This structure was based on p25 
crystal structures, which was previously reported (Tarricone et al., 2001). To determine 
if the sequence is involved in the ubiquitin-independent degradation of p35, I mutated 
Pro247 to Ala in p35 WT or p35 23R and examined the degradation of the P247A 
mutants. P35 P247A was degraded as fast as p35 WT in the presence of exogenous 
Cdk5; however, the P247A mutation made p35 23R stable (Figure 26). This was also 
found in the absence of exogenous Cdk5. When the activators were expressed alone, the 
P247A mutation did not affect the half-life of wild-type p35, but the P247A mutation of 
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p35 23R became more stable than p35 23R itself, which had a longer half-life than 
wild-type p35 (Figure 27). These results suggested that the degron-like sequence is 
involved in degradation of p35 23R either p35 23R binds to Cdk5 or not.  
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DISCUSSION 
 
p35 is an unstable protein with a half-life of 30-60 min, and it is degraded by 
proteasomes after ubiquitination (Patrick et al., 1998; Saito et al., 1998; Minegishi et al., 
2010). Because the p35 protein amount is a critical determinant of Cdk5 activity, 
elucidating the p35 degradation mechanism is central for understanding Cdk5 functions. 
To this end, I searched for the polyubiquitination site(s) in p35, but unexpectedly, I 
found that the degradation of p35 can occur without ubiquitination. I also showed that 
ubiquitin-independent degradation was mediated by an α-helical degron-like sequence 
in the C-terminal region of p35. Thus, p35 is subjected to two different degradation 
mechanisms: ubiquitin-dependent and ubiquitin-independent. The degradation speed 
was same between p35 WT and 23R in the presence of Cdk5 (Figure 19). When the 
protein levels of Cdk5 were low, p35 23R was stable more than p35 WT (Figure 20). 
Binding states of p35 to Cdk5 determines the pathway to be degraded, ubiquitin 
dependently or independently (Figure 28) (Figure 32).  
 In contrast to cell cycle Cdks, whose activation is regulated by its 
phosphorylation/dephosphorylation upon cyclin binding (Mogan et al., 1997), Cdk5 is 
activated only by binding to its activation subunit p35 (Hisanaga et al., 2010). On the 
other hand, similar to cell cycle Cdks, whose inactivation is induced by the degradation 
of cyclin, Cdk5 is inactivated by the degradation of p35 by proteasomes. Because Cdk5 
is expressed more than p35 in neurons (Lee et al., 1996; Zhu et al., 2005), the protein 
level of p35 is a limiting factor determining the total Cdk5 activity. Cyclins are typical 
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well-studied proteins to be targeted by proteasomes via ubiquitination in a cell 
cycle-dependent manner (Benati et al., 2012). Therefore, it is natural to expect that p35 
is also targeted by proteasomes when it is ubiquitinated. In fact, ubiquitination of p35 
has been demonstrated by several previous studies by groups including our lab. (Patrick 
et al. 1998, Minegishi et al., 2010; Endo et al., 2009). Therefore, it was surprising for us 
to find that the lysine-less mutant of p35 underwent degradation at a rate similar to 
wild-type p35 in cultured cell lines and primary neurons.  
 Poly-ubiquitin works as a degradation signal for proteins targeted by 
proteasomes (Kravtsova-Ivantsiv et al., 2012; Erales et al., 2014). Thus, a question 
arises as to how proteasomes recognize and degrade p35 without the polyubiquitin tag. 
Some misfolded or impaired proteins are degraded without ubiquitination by default. 
There are several examples of proteins that display default degradation, although they 
are degraded physiologically in a ubiquitin-dependent manner. p53 is a tumor 
suppressor protein that is degraded by proteasomes via polyubiquitination by E3 
ubiquitin ligases, such as Mdm2 (Tavetkov et al., 2010), but it is also degraded by the 
20S proteasome by default if its N-terminal unstructured region is not protected by 
other proteins or modification. c-Fos proto-oncoprotein is an unstructured protein and 
degraded independently of ubiquitin by proteasomes when it does not form a 
transcriptional heterodimer with a partner protein (Basbous et al., 2008). P35 functions 
exclusively as the activator of Cdk5. Only a few p35 molecules exist as free p35 in vivo 
because Cdk5 is significantly more abundant than p35. If p35 fails to bind Cdk5, 
however, p35 would be recognized as a misfolded protein and degraded without 
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ubiquitination by default. However, p35 23R appeared to maintain the proper 
conformation to fully bind and activate Cdk5, and it was degraded at a similar rate to 
that of wild-type p35. In this study, I carried out most of the experiments under excess 
amounts of Cdk5 by co-expression. Thus, I think that it is unlikely that p35 23R is 
degraded through the default pathway of degradation.  
 There are at least three types of substrate protein recognition by proteasomes 
in the ubiquitin-independent degradation systems, which are as follows: by the 19S 
regulatory particle of the 26S proteasome as an example of ornithine decarboxylase 
(ODC) (Coffino et al., 2001; Takeuchi et al., 2008); by REGg, also known as 11S or 
PA28, complexed with the 20S proteasome that is known for p21 Cdk inhibitor (Chen 
et al., 2007); and by a core subunit of the 20S proteasome as exemplified by the F 
protein of hepatitis C virus (HCV) (Yuksek et al., 2009). On the other hand, the amino 
acid sequence(s) required for degradation have also been investigated with several 
substrate proteins. In the case of the Rpn4 transcription factor that activates the 
expression of proteasome genes in yeast, the N-terminal unstructured segment and the 
following folded domain are essential for ubiquitin-independent degradation (Ha et al., 
2012). A similar requirement of two elements, including an unstructured region and a 
following a-helical sequence, is shown for thymidylate synthase (Peña et al., 2009). The 
two elements of thymidylate synthase function as a degradation signal if they are tagged 
at the C-terminus of a reporter protein and called a ubiquitin-independent degron (Melo 
et al., 2011). According to the two-step model of degradation, the α-helical degron 
region is recognized by the proteasome, and then, the disordered region enters into the 
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proteasomal cavity. P35 may be degraded similarly because p35 has an unstructured 
approximately 13 amino acids extension at the C-terminus downstream of an 
α-helix-rich domain called the cyclin fold (Figure 24).  
 NKX3.1 is a homeodomain transcription factor that regulates prostate cancer 
initiation and progression (Guan et al., 2008). NKX3.1 turnover is regulated by 
ubiquitination, but it is also proteolyzed by proteasomes independent of ubiquitination. 
This ubiquitin-independent degradation is mediated by a 21 amino acid sequence in its 
C-terminal region (Rao et al., 2012). The proline residue in the sequence is essential for 
its ubiquitin-independent degron activity. p35 has a homologous (approximately 53% 
identity) sequence at amino acids 240-258 with Pro247 in a similar position (Figure 23). 
The mutation of Pro247, which is in the ordered structure of the cyclin-fold (Tarricone 
et al., 2001), to Ala slowed the turnover rate of p35 down remarkably. Considering that 
Pro247 is positioned in the shallow concave (Figure 24), the structure, but not the amino 
acid sequence, around Pro247 may provide the proteasome recognition site. Thus, p35 
has two elements of an unstructured and a structured region next each other that 
conform to the two-step degradation as shown by other proteins displaying 
ubiquitin-independent degradation.    
 In summary, I found that p35 can be degraded by two degradation pathways; 
ubiquitin-dependent and ubiquitin-independent. The ubiquitin-independent degradation 
required the degron in the C-terminal region of p35. The ubiquitin-independent 
degradation of p35 appears to be critical for regulation of the Cdk5 activity. However, 
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the regulation mechanisms of ubiquitin-independent proteasomal degradation are 
largely unknown. Therefore, I tried to identify regulatory factors in next chapter.     
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Figure Legends 
 
Figure 1. Cell cycle Cdks and neuronal Cdk5 
Left, Cdks-Cyclins expressed in dividing cells and regulating cell cycle progression. 
Right, Cdk5-p35 is a neuronal Cdk regulating many neuronal activities.   
 
Figure 2. Regulation of Cdk5-p35 activity. 
Cdk5 is a Ser/Thr protein kinase. Cdk5 is an inactive catalytic subunit. Cdk5 is 
activated by binding p35 and recruited to membrane through myristoylation of p35. 
Cdk5 is inactivated by degradation of p35 with proteasome. 
 
Figure 3. Abnormal activation of p35  
Cdk5 is inactivated by proteasomal degradation of p35 in healthy neurons. However, 
when neurons are suffered from stressed and intercellular concentration of Ca2+ 
increased, Cdk5 is hyper activated by cleavage of p35 to p25 with calpain. Cdk5-p25 
released from membrane has longer half-life, leading to neurodegenerative diseases.  
 
Figure 4. Faster degradation of p35 bound to membrane.  
p35 is myristoylated and bound to membrane. Membrane binding accelerate the 
degradation of p35. Because p25 lack myristoylation site, p25 is more stable than p25. 
N7-p25, which binds to membrane, is degraded faster than p25.  
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Figure 5. The schematic diagram of ubiquitin proteasome system. 
E1 activates ubiquitin. Activated ubiquitin bind E2. E3 ligase complexed with E2 
transfers activated ubiquitin to a substrate through isopeptide bond. Poly ubiquitination 
occurs by repeating of chain reaction. Poly ubiquitination of the substrate is recognized 
by 19S regulatory particles of 26S proteasome and then the substrate is proteolyzed in 
the cavity of 20S proteasome.  
 
Figure 6. Various types of poly ubiquitination. 
K48 poly ubiquitination is a degradation signal, which is recognized by 26S proteasome. 
The K63 poly ubiquitination regulates DNA repair and membrane trafficking. The 
linear poly ubiquitination (N-terminal linkage) regulates NFκB activation. Other types 
of polyubiquitination remain to be investigated.  
 
Figure 7. Schematic representation of the p35 molecule.  
 p35 consist of the N-terminal p10 and the C-terminal p25, Cdk5 activation domain. 
Calpain (scissor) cleaves p35 into p10 and p25. Ks indicate possible ubiquitination 
lysine sites. Phosphorylation at Thr138 stimulates proteasomal degradation of p35. 
C-terminus two lysine residues of p53 are known to be ubiquitination sites of p53. Two 
lysine residues are also present in p35. 
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Figure 8. Effect of Arg mutations at these possible ubiquitination sites on the 
degradation of p35. 
 Hek 293 cells were transfected with p35 or its arginine mutants K126/127R, K140R, 
K167R, or K298/299R by PolyFect. 24 hours after transfection, the cells were treated 
with cycloheximide (CHX) for 1 or 3 hours. The amounts of p35 protein were assessed 
by immunoblotting with anti- p35 antibody (C19) (top panel). Cdk5 is indicated in 
middle panel. Actin is shown as loading control (lower panel).  
 
Figure 9. Schematic representation of N7-p25 and sites of Arg mutations 
 Upper panel represents N7-p25. N7-p25 is a fusion of p25 with the N-terminal seven 
amino acids of p35. The N7 peptide includes second amino acid Gly, which is a 
myristoylation site. Because p35 is anchored to membrane via this myristoylation, 
N7-p25 is also localized on membrane. N7-p25 contain 10 lysine residues, and Myc tag 
also contain a lysine residue. The positions of the Lys residues are indicated by arrows. 
Lower panel indicated mutation sites of each mutant.  
 
 Figure 10. Degradation of Arg mutants of N7-p25 in Neuro2a cells. 
 (A) Neuro2A cells were co-transfected N7-p25 or its Arg mutants with Cdk5 by 
HillyMax. 24 hours after transfection, the cells were treated with cycloheximide (CHX) 
for 3 hours. After the treatment, the cells were collected and lysed in sample buffer. The 
protein amounts of N7-p25 were calculated by Western Blotting. N7-p25 was detected 
by anti-Myc antibody (upper panel). Cdk5 is middle and a Actin is shown in lower 
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panel as internal control. 
 B Quantification of (A). Levels of p35 at 3h are represented as the ration of control 
(0h). 
 
Figure 11. Ubiquitination of N7-p25 and its Lys-to-Arg mutants 
 N7-p25 and its Arg mutants were expressed with HA-ubiquitin in Neuro2a cells and 
immunoprecipitated by anti-p35. Ubiquitination was assessed by immunoblotting with 
anti-HA antibody (middle) and anti-polyubiquitin (PolyUb) antibody (right). Input is 
shown in the right panel. 
 
Figure 12. Cdk5 binding and activation ability of Arg mutants of N7-p25  
  N7-p25 or N7-p25 11R was co-transfected with Cdk5 into Neuro2A cells. The 
binding of N7-p25 or N7-p25 11R to Cdk5 was assayed by the coimmnoprecipitation 
with anti-Cdk5. The kinase activity was measured by the phosphorylation of histone H1 
using [γ-32P] ATP. The autoradiograph is shown in the bottom, and quantification is 
shown on the right.  
 
Figure 13. Arg mutations of all of the Lys residues in p35 
The upper is p35, Lysine residues in which are indicated by arrows. There are 23 lysine 
residues on p35. Amino acid number of all lysine residues are shown below. p35 23R is 
the mutant, whose all lysine residues were replaced by arginine. 
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Figure 14. Ubiquitination of p35 and p35 23R 
 Neuro2A cells were transfected p35 (WT) or p35 23R (23R). 24 hours after 
transfection, the cells were treated with MG132 for 5 hours. The cells were collected 
and immunoprecipitated with anti-p35 (C19) antibody. Polyubiquitination of p35 was 
detected by Western Blotting with anti-poly Ub antibody (FK2). p35 and actin in input 
are shown below. 
 
Figure 15. p35 23R is also degraded by proteasome 
 Neuro2A cells were cotransfected with p35 (WT) or p35 23R (23R) and Cdk5 using 
HillyMax. 24 h after transfection, the cells were treated with CHX in the presence or 
absence of the proteasome inhibitor Epoxomicin or MG132 for 5 h. Protein levels of 
p35 was detected by western blotting with anti-p35 (C19) antibody. Left panel indicated 
p35 WT and right is p35 23R.  
 
Figure 16. Binding and activation ability of p35 23R mutant. 
 p35 WT and 23R were co-overexpressed with Cdk5 in Neuro2A cell. 24 h after 
transfections, p35 was immunoprecipitated with anti-Cdk5 (DC17), and their binding to 
p35 23R was examined by the immunoblotting of p35 in the Cdk5 immunoprecipitates. 
The kinase activity was measured by the phosphorylation of histone H1 (H1). Histone 
H1 phosphorylation is quantified in the right panel. 
 
 32 
Figure 17. Phosphorylation of p35 and p35 23R. 
p35 was expressed with or without Cdk5 in Neuro2A cells, Phosphorylation states of 
p35 were analyzed by Phos-tag SDS-PAGE. The phosphorylation states of the 
respective bands are indicated at the left side of the blot, based on the results by 
Hosokawa et al. (2010). The upper two panels are immunoblotted with anti-p35 and 
anti-Cdk5 after Laemmli’s SDS-PAGE.    
 
Figure 18. Subcellular localizations of p35 and p35 23R 
 p35 or p35 23R were overexpressed in Neuro2A cells. 24 h after transfection, the cell 
were fixed by paraformaldehyde. After the fixation, these cells were immunostained by 
anti-p35 antibodies. The nuclear was stained with DAPI       
 
Figure 19. Expression levels of p35 or p35 23R in the presence or absence of Cdk5 
at steady states 
 p35 was overexpressed with or without Cdk5. 24 h after transfection, the cells were 
collected. Expression levels were analyzed by immunoblotting with anti-p35 shown 
(top), anti-Cdk5 (middle) and anti-actin (bottom). 
 
Figure 20. The degradation rates of p35 in the presence of Cdk5 
 Neuro2a cells expressing Cdk5 and p35 (WT) or p35 23R (23R) were treated with 
CHX for the indicated times. p35 was detected by immunoblotting with anti-p35. Cdk5 
is shown in middle. Actin is the loading control (lower). The quantification is shown in 
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the lower panel.  
 
Figure 21. p35s degradation rates in the absence of Cdk5 
Neuro2a cells expressing p35 (WT) or p35 23R (23R) were treated with CHX for the 
indicated times. P35 was detected by immunoblotting with anti-p35. Actin is the 
loading control. Quantification is shown in lower panel (mean ± SEM, n = 3, *p < 0.05, 
Tukey’s post hoc test). 
 
Figure 22. Degradation of p35 23R in primary neurons. 
 Cerebral cortical neurons was expressing p35-HA (WT) or p35-HA 23R (23R) were 
treated with CHX for the indicated times. P35 (WT) and p35 23R (23 R) were detected 
by immunoblotting with anti-HA antibody. Cdk5 and actin are shown in middle and 
lower panels, respectively. Quantification is shown below (mean ± SEM, n = 3). 
 
Figure 23. The degron-like amino acid sequence in p35. 
Amino acids 240-258 of p35 display a similarity to the ubiquitin-independent degron of 
NKX3.1. Pro221 in NKX3.1 is a critical amino acid for degron activity. A 
corresponding amino acid in p35 is Pro 247 
 
Figure 24. The position of Pro247 in p25. 
 A ribbon structure of p25 is depicted using a Waals software (Altif Laboratories, Inc., 
Tokyo, Japan) based on the crystal structure of p25 (Tarricone et al., 2001). Pro247 is 
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located between α3 and α5 helices.  
 
Figure 25. The structures of p25 depicted by a space filling model.  
 The structure of p25 is shown by the space filling model using the Waals software 
(Altif Laboratories Inc., Japan). The side chains of Pro247 (blue) is exposed in the 
surface of p25.  
 
Figure 26. The degradation of Ala mutants at Pro247 of p35 in the presence of 
Cdk5 
 Neuro2a cells expressing Cdk5 and p35 (WT), its Ala mutant (P247A), p35 23R, or 
p35 23R P247A (23R-P247A) were treated by CHX for 0, 3 or 6 h and then protein 
amount of p35 were analyzed by Western blotting with anti-p35. (the mean ± SEM, n = 
3, *P < 0.05, **P < 0.01, ***P < 0.001, Tukey’s post hoc test) 
 
Figure 27. Degradation of Ala mutants at Pro247 of p35 in the absence of 
exogenous Cdk5.  
 p35 (WT) or one of its mutants, p35 P247A, p35 23R or p35 23R P247A was 
expressed in Neuro2A cells, and the degradation rate was measured by immunoblotting 
with anti-p35. Cdk5 and actin were also shown. Lower panels are for quantification (the 
mean ± SEM, n = 3, *P < 0.05, **P < 0.01, Tukey’s post hoc test). 
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Figure 28. The Cdk5-binding determines the pathway of p35 to be degraded 
 p35 WT and p35 23R displayed similar degradation rate when they bound to Cdk5. 
This results suggest that the degradation of Cdk5-bound p35 is curried out in a 
ubiquitin-independent manner (upper). In contrast, the degradation of p35 23R was 
slower than p35 WT, when p35 did not bind to Cdk5 (Lower), suggesting that free p35 
is degraded by ubiquitin dependently. 
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Chapter2 
Searching for protein factors involved in ubiquitin 
-independent degradation of p35. 
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Summary 
 
  In order to identify protein factors in ubiquitin-independent proteasomal degradation, 
p35 binding proteins were prepared by immunoprecipitation of p35, and analyzed by  
mass spectroscopy. Among the many proteins identified, there were PA28 family 
proteins, which are known to promote several ubiquitin-independent degradation. I 
examined their interactions and effect on p35 degradation. However, PA28 
co-expression did not affect degradation of p35 and was not detected in p35 
immunoprecipites. These results suggest that ubiquitin-independent degradation of p35 
require a regulator other than PA28. There are still many other candidates in the list of 
MS-spectrometry analysis, I hope there would be a regulator protein of 
ubiquitin-independent degradation in the list.     
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Introduction 
 
 As described in chapter 1, ubiquitin-independent degradation appears to be 
mediated by a particular degron sequence. An example is the ubiquitin-independent 
degron of Nkx3.1. It was reported to work as a portable degron (Rao et al., 2012). When 
EGFP was fused with this degron, GEP was destabilized. This fact indicates 
ubiquitin-independent proteasomal degradation of a folded protein can be regulated by 
these sequences. I thought it is also a selective degradation system. However, the 
regulation mechanisms of ubiquitin-independent degradation are largely unclear yet. 
Ubiquitin-independent proteasomal degradation is also fast as ubiquitin-dependent 
degradation. I wondered how ubiquitin-independent degradation is regulated by these 
degrons. Many other degrons recruit E3 ligase and induce the ubiquitination (Ravid et 
al., 2008). In contrast, ubiquitin-independent degron does not induce ubiquitination. If 
so, there should be a surrogate regulative mechanism. A possibility is that the substrates 
of ubiquitin-independent degradation are recognized and bound proteasomal subunits 
directly. Another possibility is that regulation factor is involved in the recognition 
independent of ubiquitin and carry it to proteasome. In order to identify the mechanism, 
I search for the regulators of ubiquitin-independent degradation for p35.  
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Materials and Methods 
 
Cell culture and transfection 
 Neuro2A cells were cultured as described in Chapter 1. Neuro2A cells were 
transfected with expressions of p35 or p35 23R P247A plasmid using 
polyethylene-imine Max (PEI Max) (Polysciences Inc. PA, USA).  
 
Construction of expression vectors 
 PA28α (Psme 1), PA28β (Peme2) and PA28γ (Psme3) in pCDNA6 were obtained 
from OriGene Technologies (Rockville, MD, USA). p35 WT or 23R-P247A tagged 
with HA Flag were amplified by PCR using p35 or its mutants in pCAGMCS2 as a 
template with 5’- GTTAAGCTTATGGGCACGGTGCTGTC -3’ as a forward primer 
and 5’- TGCTACAAGGTCTAATGCGACTGATGTTTCTGCTACTGCTGTTCAC 
TGGATCCTAT -3’ as a reverse primer. PCR products were digested by HindⅢ and 
BamHⅠand then ligated into pCAGMCS2 at same sites.  
 
LC-MS analysis 
 p35-HA-Flag or p35 23R P247A-HA-Flag was transfected in Neuro2A cells. 24 h 
after transfection, the cells were collected and lysed in 20 mM MOPS pH 6.8, 1 mM 
EGTA, 0.1 mM EDTA, 0.15 M NaCl, 1 mM MgCl2, 10 µg/ml leupeptin, 0.4 mM 
Pefabloc, and 0.3% (v/v) Nonidet P-40. After the centrifugation at 15000×g for 15 min 
at 4℃, p35 was immunoprecipitated with anti-Flag M2 antibody, and then eluted by a 
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DYKDDDK Flag peptide (Wako, Japan). After concentration by the methanol 
chloroform precipitation, the proteins were separated by SDS-PAGE using a 5-20 % 
polyacrylamide gradient gel (SuperSep, Wako, Japan). The gels were excised and 
incubated by trypsin. The trypsin digests were eluted from gel and then analyzed by a 
Liquid Chromatography-Mass Spectrometry analyzer (Q Exactive plus, Thermo Fisher).      
 
Methanol Chloroform precipitation method 
 Proteins were precipitated by 43% methanol and 10% chloroform. After the 
centrifugation at 15000×g for 5 min at 4℃, the upper layer was removed. After 
repeating this step, 2.25 times of methanol were added to the middle and lower layers 
and gently mixed. The mixture was centrifuged at 15000×g for 5 min at 4℃ and the 
supernatant was removed. The precipitate was dried up by evaporation and then 
dissolve in SDS-PAGE sample buffer.      
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Results 
 
p35 WT or 23R P247A binding proteins 
In order to identify protein factors regulating ubiquitin-independent proteasomal 
degradation of p35, I searched for binding proteins of p35WT or 23R-P247A. p35 were 
tagged with HA and Flag and expressed in Neuro 2A cells. p35 or p35 23R-P247A was 
immunoprecipitated with anti-Flag antibody and eluted with the flag peptides. The 
results of Gradient SDS-PAGE of these samples were shown in Figure 29. Identified 
proteins that showed interaction to p35 were subjected to LC-MS analysis, and there are 
indicated in TableⅠ. I compared their binding score between p35 WT and 23R-P247A. 
p35 WT specific binding protein were shown in TableⅡ . These proteins were 
considered to be candidates of regulating factor of ubiquitin-independent degradation of 
p35.   
 
PA28 did not bind to p35 directly nor affect the degradation of p35. 
 Among many proteins identified, I was interested in PA28, proteasomal activator, 
because PA28 binds proteasomes and operates the proteasomal degradation ubiquitin 
independently (Chen et al. 2007). PA28 is hetero-hexamer or heptamer of alpha and 
beta or homo-hexamer or heptamer of gamma (Song et al., 1996). I examined whether 
PA28 affects degradation of p35. p35 were transfected with PA28 α/β, or γ in Neuro2a 
cells, and the degradation of p35 was examined by CHX chase assay. However, the rate 
of p35 degradation was not different between the presence or absence of PA28, either α 
  70 
/ β or γ (Figure 30). Next I tested the direct interaction between p35 and PA28 by 
immunoprecipitation, but I did not detect their direct interaction (Figure 31). These 
results suggest that PA28 neither α/β nor γ may not be a protein to recruit p35 to 
proteasome.  
      
  
  71 
Discussion 
 
PA28-bound proteasome carries out several ubiquitin-independent 
degradations (Chen et al., 2007; Yersak et al., 2017). PA28 forms heptamer or hexamer 
and binds 20S proteasome. The PA28 complexes open the entrance of proteasome. 
However, it is unknown yet how ubiquitin-independent degradation by PA28 is 
regulated. It is not known which of PA28 directory binds to substrate and requites 
proteasome or requires another intermediate regulator. Because, I found PA28 α, β and 
γ in the list of p35-binding proteins, I thought that PA28 would be a factor mediating 
the ubiquitin-independent degradation of p35. In generally, while the complexes of 
PA28 α/β activate all protease activity, the complexes of PA28γ activate only trypsin 
like activities (Realini et al. 1997). Additionally, PA28 α / β  is present in cytoplasm, 
PA28γ localized in nuclear (Masson et al. 2009). Although p35 is a cytoplasmic protein 
bound to membranes, I examined the effect of PA28 α / β and γ on the degradation of 
p35. Unfortunately, PA28 overexpression did not affect the degradation of p35 (Figure 
32), nor PA28 interacted with p35 directly. It is not known well how protein substrates 
to be degraded are targeted from PA28 binding proteasome. I have a hypothesis; it may 
require another recruiting intermediate protein (Figure 33). Another possibility, another 
types of proteasome degraded p35 ubiquitin independently. In the future, I want to 
identify the regulator of ubiquitin-independent degradation of p35. I hope that such a 
protein is included in the list of p35-binding proteins. Therefore, the list of p35 binding 
proteins would be important for understanding the regulation mechanism of 
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ubiquitin-independent proteasomal degradation, depending on folding degrons. Another 
interesting things are that there are several E3 ligases such as UBR family, HECTD and 
UFM1 in the list. There could be a p35 ubiquitin ligase, which has not been identified in 
the brain yet. It would be interesting to examine the possibility in the future.  
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Figure Legends 
 
Figure 29 Binding proteins of p35 WT and 23R-p247A. 
p35 WT or p35 23R tagged with HA and Flag were transfected in Neuro2A cells. p35 
were immunoprecipitated with anti-Flag antibody and eluted by a DYKDDDK Flag 
peptides. The eluate was concentrated by methanol-chloroform methods and then was 
subjected to SDS-PAGE using 5-20 % gradient gel (Super step, Wako) Lane 1, WT; 
Lane 2, 23R; Lane 3, untransfected. Both side lanes are molecular weight markers 
(Precision Plus Protein Standards Dual Color, BIO-RAD).  
 
Figure 30 Effect of PA28 on the degradation of p35 
 p35 WT or 23R was co-transfected with PA28 α/β, or γ. 24 h after transfection, the 
cells were treated with CHX for the indicated times. The protein levels were analyzed 
by Western Blotting. p35 WT (left) and p35 23R (Right) were detected by 
immunoblotting with anti-p35 antibodies. Lower panels are quantification.  
 
Figure 31 PA28 does not bind to p35 directly. 
 p35-HA-Flag were overexpressed with or without PA28 in Neuro2A cells. 24 h after 
transfection, p35 was immunoprecipitated with anti-HA antibody. Immunoprecipitates 
were shown upper. Lysates were displayed in the lower panel.   
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Figure 32 A scheme describing two degradation pathways  
 There are two different pathways for degradation of p35, ubiqtuitin-dependent and 
-independent. These degradation systems may be used differently depending on cellular 
conditions. p35 bound to cdk5 is degraded by proteasome in a ubiquitin-independent 
manner for the inactivation of Cdk5. Ubiquitin-dependent degradation proceed for free 
p35.   
 
Figure 33 Possible regulation mechanism of ubiquitin-independent degradation 
  Ubiquitin independent degradations of p35 could be reregulated by additional 
proteins, which recruit p35 to 26S proteasome or PA28-bound 20S proteasome.     
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General discussion 
 
The regulation mechanism of p35 degradations 
In this thesis, I investigated the molecular mechanisms of p35 degradation and found 
that there are two degradation pathways, ubiquitin-dependent and -independent. 
Cdk5-p25 is a multifunction protein kinase in mammalian brain, playing roles from 
neuronal development to neuron cell death. Especially, when the cells are exposed in 
stress condition, p35 is cleaved to p25. Cdk5-p25 is activated abnormally and would 
cause neurodegeneration (Patrick et al., 1999; Kusagawa et al., 2000; Lee et al., 2000; 
Cruz et al., 2004). Therefore, it is very important to elucidate the regulation mechanism 
of Cdk5-p35. Previously, it was shown that p35 was degraded by ubiquitin-proteasome 
system. Therefore, I thought the degradation of p35 should be mediated via 
ubiquitination, and the identification of E3 ligases of p35 was critical. However, in this 
study, I found for the first time that p35 was degraded in a ubiquitin independent 
manner by proteasome (Figure 15), indicating that there are two regulation mechanisms 
in the proteasomal degradation of p35. One is ubiquitin-dependent and another is 
ubiquitin-independent. 
In order to clarify the regulation mechanisms of the protein amount of p35, I 
need to reveal both the specific E3 ligase of p35 and possible regulator of 
ubiquitin-independent degradation. I was interested in ubiquitin-independent system 
because this degradation seems more important in metabolism of p35, and then focused 
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on ubiquitin-independent degradation of p35 in the latter part of this study. Then, I 
found the degron sequence in the C-terminus globular region of p35, based on the 
sequence similarity to that in Nkx3.1. However, it is unknown how this degron 
promotes ubiquitin-independent degradation of target proteins. There are several types 
of ubiquitin-independent degradations. PA28 is suggested to be involved in some 
ubiquitin-independent degradation. Since I identified PA28 as a p35 binding protein. I 
examined if PA28 interacts and promotes ubiquitin-independent degradation of p35. 
However, PA28 did not bind p35 nor increase the degradation of p35. I thought it may 
require another regulator in order to recruit p35 to proteasome. This is a future question 
to be investigated. 
 
Significance of ubiquitin-dependent and -independent degradation  
The physiological role of ubiquitin-independent degradation and its regulation are 
largely unknown, although such protein degradations have been reported 
(Kravtsova-Ivantsiv et al., 2012; Erales et al., 2014). In the case of p21, its degradation 
in the resting state of cells is ubiquitin-independent (Chen et al., 2007; Zhang et al., 
2004), whereas cell cycle-dependent degradation is ubiquitin-dependent (Abbas et al., 
2008; Bornstein et al., 2003). I think similar differential usage of the degradations may 
be operated for p35. P35 is an unstable and short half-life protein in neurons and 
cultured cell lines exogenously expressed. Because p35 P247A showed a similar 
degradation rate to wild-type p35 in cultured cells, the degradation of p35 in dividing 
cells may operate in ubiquitin dependently. In contrast, p35 is acutely degraded in 
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neurons when treated with glutamate (Wei et al., 2005; Hosokawa et al., 2006). This 
stimulated degradation of p35 may be operated in ubiquitin independently. In any cases, 
rapid p35 turnover would be crucial for neurons to survive for their long life. 
Overactivation of Cdk5, which is produced by cleavage of p35 to p25, is toxic for 
neurons. The longer half-life of p35 may enhance a probability of the overproduction of 
p25. Two degradation pathways for p35 would be a mechanism to assure the long life of 
neurons.  
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TableⅠ Coimmunoprecipitated proteins with p35 identified  (Score > 4) 
Protein name 
WT specific 
Binding Score 
(WT/mutants) 
Binding Score 
(p35 WT) 
Cyclin-dependent kinase 5 activator 1  3.4  44.6  
Exosome complex exonuclease RRP44  1.0  35.0  
Eukaryotic translation initiation factor 4 gamma 2 0.7  26.0  
Serine/threonine-protein kinase SIK3  4.0  24.2  
STIP1 homology and U box-containing protein 1  1.1  24.2  
E3 ubiquitin-protein ligase UBR4  2.1  21.0  
mRNA cap guanine-N7 methyltransferase  0.6  18.0  
Ran GTPase-activating protein 1  1.9  17.2  
Small subunit processome component 20 homolog O 1.7  17.2  
Retrotransposon-like protein 1  2.5  15.5  
E3 ubiquitin-protein ligase HECTD1 0.8  15.5  
MICOS complex subunit Mic60  1.4  15.0  
Probable ATP-dependent RNA helicase DDX46 0.9  14.0  
MICOS complex subunit Mic19 1.9  13.1  
Lipoamide acyltransferase component of branched-chain 
alpha-keto acid dehydrogenase complex, mitochondrial  
0.6  13.0  
Dehydrogenase/reductase SDR family member 7B 1.1  12.0  
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5'-AMP-activated protein kinase subunit beta-1  0.5  12.0  
5'-AMP-activated protein kinase subunit gamma-1  0.6  11.3  
Sorting and assembly machinery component 50 homolog  2.8  11.1  
Extended synaptotagmin-2  1.8  11.1  
Neuron navigator 1 0.9  11.1  
Potassium-transporting ATPase alpha chain 2  1.1  11.0  
Proteasome activator complex subunit 1 1.1  11.0  
Protein TANC2  1.0  11.0  
Reticulocalbin-2 0.5  11.0  
Hsc70-interacting protein 1.1  10.5  
Signal recognition particle 19 kDa protein 1.7  10.1  
Ubiquitin carboxyl-terminal hydrolase 34 3.3  10.0  
E3 UFM1-protein ligase 1 2.5  10.0  
Mitochondrial import receptor subunit TOM70 1.7  10.0  
RNA polymerase II-associated protein 1 1.4  10.0  
RNA-binding protein 25 0.6  10.0  
Gamma-tubulin complex component 2 1.1  9.1  
Ancient ubiquitous protein 1 0.6  9.1  
Ataxin-2 0.4  9.1  
Cytochrome c oxidase subunit 5B 1.5  9.0  
MICOS complex subunit MIC13  1.5  9.0  
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Protein transport protein Sec61 subunit gamma 1.1  9.0  
Small nuclear ribonucleoprotein G 1.0  9.0  
CDK5 regulatory subunit-associated protein 3  4.0  8.1  
Ubiquitin carboxyl-terminal hydrolase 16 4.0  8.1  
ELKS/Rab6-interacting/CAST family member 1  1.0  8.1  
Serine/threonine-protein kinase mTOR  8.0  8.0  
Protein LLP homolog  2.3  8.0  
Pleckstrin homology domain-containing family H member 
3 1.6  8.0  
PDZ and LIM domain protein 7 1.0  8.0  
5'-AMP-activated protein kinase subunit beta-2 0.9  8.0  
5'-AMP-activated protein kinase subunit gamma-2 0.6  8.0  
Melanoma inhibitory activity protein 3 1.7  7.6  
Sodium/potassium-transporting ATPase subunit alpha-4 1.1  7.5  
Ribosome-binding protein 1 1.2  7.3  
Intraflagellar transport protein 122 homolog 7.0  7.1  
Vacuolar protein sorting-associated protein 53 homolog 7.0  7.1  
26S proteasome non-ATPase regulatory subunit 9 3.5  7.1  
E3 ubiquitin-protein ligase HERC2 2.3  7.1  
Alanine-tRNA ligase, mitochondrial 2.3  7.1  
RNA-binding protein 28 1.8  7.1  
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MKI67 FHA domain-interacting nucleolar phosphoprotein 1.4  7.1  
Small glutamine-rich tetratricopeptide repeat-containing 
protein alpha  
1.4  7.1  
CDKN2AIP N-terminal-like protein  1.2  7.1  
Dolichyl-diphosphooligosaccharide--protein 
glycosyltransferase subunit STT3A  
1.0  7.1  
26S proteasome non-ATPase regulatory subunit 5  2.3  7.0  
Serine dehydratase-like 2.3  7.0  
Protein MON2 homolog 1.8  7.0  
DDRGK domain-containing protein 1 1.4  7.0  
Protein phosphatase 1A 1.3  7.0  
2-methoxy-6-polyprenyl-1,4-benzoquinol methylase, 
mitochondrial 
1.2  7.0  
CLIP-associating protein 1 1.0  7.0  
HCLS1-associated protein X-1 0.9  7.0  
Proteasome activator complex subunit 2 0.6  7.0  
Cytochrome c oxidase subunit 2 0.5  7.0  
Plectin  2.1  6.5  
Importin-11 1.3  6.5  
Potassium-transporting ATPase alpha chain 1  1.1  6.5  
Ubiquitin-like protein 4A 0.9  6.5  
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Proteasome subunit alpha type-2 0.8  6.3  
Calcium-binding mitochondrial carrier protein Aralar1 1.4  6.1  
Protein scribble homolog 3.0  6.1  
DNA mismatch repair protein Mlh1 2.0  6.1  
Regulator of microtubule dynamics protein 3 1.5  6.1  
Ubiquitin carboxyl-terminal hydrolase isozyme L5 1.5  6.1  
Serine/threonine-protein kinase ATR 1.2  6.1  
Nucleoplasmin-3 1.0  6.1  
Ras-related protein Rab-10 0.9  6.1  
Terminal uridylyltransferase 7 0.7  6.1  
Astrotactin-1  2.0  6.0  
Long-chain-fatty-acid--CoA ligase 5 1.5  6.0  
E3 ubiquitin-protein ligase RBX1 1.5  6.0  
Stathmin-3 1.5  6.0  
Serine/threonine-protein kinase DCLK1 1.0  6.0  
Protein PRRC2B 0.9  6.0  
Splicing factor 1 0.7  6.0  
Proteasome subunit beta type-8 0.5  6.0  
Nucleophosmin 1.1  5.9  
IgE-binding protein 1.0  5.5  
60S ribosomal protein L22-like 1 1.4  5.5  
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DnaJ homolog subfamily B member 12 0.8  5.4  
RRP15-like protein 1.5  5.3  
Protein phosphatase 1B 1.5  5.3  
26S protease regulatory subunit 6B 0.9  5.3  
60S acidic ribosomal protein P1 1.1  5.2  
Patatin-like phospholipase domain-containing protein 7 5.0  5.1  
Adenylate kinase isoenzyme 6 2.5  5.1  
Serine/threonine-protein kinase RIO3 2.5  5.1  
Spermatogenesis-associated serine-rich protein 2 2.5  5.1  
DIS3-like exonuclease 1 1.7  5.1  
Lysophospholipid acyltransferase LPCAT4 1.7  5.1  
Dual specificity mitogen-activated protein kinase kinase 3 1.3  5.1  
Prothymosin alpha 1.3  5.1  
E3 ubiquitin-protein ligase RING2 1.3  5.1  
Protein FAM195B 1.0  5.1  
G-protein coupled receptor-associated sorting protein 2 1.0  5.1  
Acyl-CoA:lysophosphatidylglycerol acyltransferase 1 1.0  5.1  
Arginine and glutamate-rich protein 1 0.7  5.1  
Nuclear nucleic acid-binding protein C1D 0.6  5.1  
BAG family molecular chaperone regulator 5 0.4  5.1  
ATP-dependent RNA helicase DDX51 5.0  5.0  
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Cyclin-K  2.5  5.0  
DmX-like protein 2 2.5  5.0  
Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma 1.7  5.0  
Nucleosome assembly protein 1-like 4 1.4  5.0  
Cytochrome c oxidase subunit 6C 1.3  5.0  
Kinetochore-associated protein 1 1.3  5.0  
Mitochondrial ornithine transporter 1 1.0  5.0  
Small ubiquitin-related modifier 1 1.0  5.0  
DnaJ homolog subfamily C member 7 0.9  5.0  
Methyl-CpG-binding domain protein 3 0.8  5.0  
NEDD8 ultimate buster 1 0.8  5.0  
Mitochondrial import receptor subunit TOM20 homolog 0.7  5.0  
Synaptosomal-associated protein 47 0.6  5.0  
26S proteasome non-ATPase regulatory subunit 4 0.6  5.0  
Chromobox protein homolog 3 0.5  5.0  
Sequestosome-1 1.4  4.8  
CDP-diacylglycerol--inositol 3-phosphatidyltransferase 1.1  4.8  
Proteasome activator complex subunit 3 0.9  4.8  
Plasma membrane calcium-transporting ATPase 2 1.4  4.7  
Brefeldin A-inhibited guanine nucleotide-exchange protein 
2 0.7  4.7  
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Importin-7 1.5  4.6  
Ras GTPase-activating-like protein IQGAP1 1.8  4.5  
Mitotic-spindle organizing protein 2 1.3  4.5  
Transmembrane emp24 domain-containing protein 10 1.0  4.5  
Pericentriolar material 1 protein 0.3  4.5  
26S proteasome non-ATPase regulatory subunit 13 0.8  4.4  
Proteasome subunit beta type-3 1.2  4.4  
Golgi to ER traffic protein 4 homolog 1.0  4.4  
Testis-expressed sequence 10 protein 1.4  4.3  
Luc7-like protein 3 1.3  4.3  
60S ribosomal protein L36 0.9  4.3  
Desmoplakin 4.2  4.2  
CDKN2A-interacting protein 1.4  4.2  
Afadin 1.2  4.1  
Proteasome subunit beta type-1 0.8  4.1  
CLIP-associating protein 2  2.0  4.0  
ER membrane protein complex subunit 8 2.0  4.0  
Ectoderm-neural cortex protein 1 2.0  4.0  
Nuclear valosin-containing protein-like 2.0  4.0  
DNA repair protein RAD51 homolog 1 2.0  4.0  
Macrophage erythroblast attacher  2.0  4.0  
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Tumor suppressor candidate 3  2.0  4.0  
p53 and DNA damage-regulated protein 1  1.6  4.0  
Ras GTPase-activating protein 3 1.6  4.0  
Cytochrome c oxidase assembly factor 3 homolog, 
mitochondrial 
1.3  4.0  
Mitochondrial glutamate carrier 2  1.3  4.0  
2-amino-3-ketobutyrate coenzyme A ligase, mitochondrial 1.3  4.0  
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex 
subunit 5  
1.3  4.0  
Peptidyl-tRNA hydrolase 2, mitochondrial  1.3  4.0  
Hamartin  1.3  4.0  
Zinc finger CCCH domain-containing protein 8 1.3  4.0  
NFX1-type zinc finger-containing protein 1  1.3  4.0  
Importin-8  1.3  4.0  
2-oxoglutarate and iron-dependent oxygenase 
domain-containing protein 3 
1.3  4.0  
26S proteasome non-ATPase regulatory subunit 14  1.1  4.0  
ADP-ribosylation factor-like protein 8A  1.0  4.0  
ATP synthase F(0) complex subunit B1, mitochondrial 1.0  4.0  
DDB1- and CUL4-associated factor 5 1.0  4.0  
Isocitrate dehydrogenase [NADP], mitochondrial  1.0  4.0  
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Protein misato homolog 1 1.0  4.0  
Peroxisome biogenesis factor 1 1.0  4.0  
Pterin-4-alpha-carbinolamine dehydratase 2 1.0  4.0  
E3 ubiquitin-protein ligase TRIM32 1.0  4.0  
Medium-chain specific acyl-CoA dehydrogenase, 
mitochondrial 
1.0  4.0  
Uncharacterized aarF domain-containing protein kinase 1 1.0  4.0  
Non-histone chromosomal protein HMG-14 1.0  4.0  
HEAT repeat-containing protein 5B 1.0  4.0  
E3 ubiquitin-protein ligase RNF181  1.0  4.0  
Ribonuclease P protein subunit p25 1.0  4.0  
RWD domain-containing protein 4 1.0  4.0  
GPI transamidase component PIG-S  0.9  4.0  
Ferritin heavy chain  0.8  4.0  
Cysteine desulfurase, mitochondrial 0.8  4.0  
Transcription elongation factor SPT4-A 0.8  4.0  
Transcription elongation factor SPT4-B  0.8  4.0  
ER degradation-enhancing alpha-mannosidase-like 
protein 3 
0.8  4.0  
Ubiquitin-conjugating enzyme E2 G2  0.8  4.0  
Pleckstrin homology-like domain family B member 1 0.7  4.0  
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DnaJ homolog subfamily C member 16 0.7  4.0  
Sarcoplasmic/endoplasmic reticulum calcium ATPase 3 0.7  4.0  
DnaJ homolog subfamily B member 6 0.7  4.0  
RNA demethylase ALKBH5 0.6  4.0  
Brefeldin A-inhibited guanine nucleotide-exchange protein 
1 0.6  4.0  
Adhesion G protein-coupled receptor L2 0.6  4.0  
Mitochondrial import receptor subunit TOM22 homolog 0.5  4.0  
Ankyrin repeat, SAM and basic leucine zipper 
domain-containing protein 1  
0.4  4.0  
GPI-anchor transamidase  0.3  4.0  
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TableⅡ The candidates of ubiquitin independent proteasomal degradation (Binding 
Score > 4) 
Protein name 
WT specific 
Binding Score 
(WT/mutants) 
Binding Score 
(p35 WT) 
Junction plakoglobin  12  2  
Epiplakin  9  1  
Serine/threonine-protein kinase mTOR  8  8  
Intraflagellar transport protein 122 homolog  7  7  
Vacuolar protein sorting-associated protein 53 homolog  7  7  
Dynein light chain Tctex-type 1  6  3  
Thyroid adenoma-associated protein homolog 6  2  
Heterochromatin protein 1-binding protein 3 6  1  
Patatin-like phospholipase domain-containing protein 7  5  5  
ATP-dependent RNA helicase DDX51  5  5  
Beta-centractin 5  1  
Poly(A) RNA polymerase, mitochondrial  5  1  
Transcription factor COE3  5  0  
E3 ubiquitin-protein ligase UBR2 5  3  
Nck-associated protein 1  5  1  
  95 
Desmoplakin  4  4  
CDK5 regulatory subunit-associated protein 3  4  8  
Ubiquitin carboxyl-terminal hydrolase 16 4  8  
Synaptic vesicle glycoprotein 2C 4  4  
AP-3 complex subunit sigma-2 4  4  
Cyclin-dependent kinase 13 4  4  
Mitochondrial import inner membrane translocase subunit 
TIM14 4  4  
Vacuolar protein sorting-associated protein 4A  4  4  
Toll-interacting protein  4  4  
Methyltransferase-like protein 13 4  2  
Protein odr-4 homolog 4  2  
WD repeat domain-containing protein 83 4  2  
Signal transducing adapter molecule 1 4  2  
Chromosome alignment-maintaining phosphoprotein 1  4  1  
DDB1- and CUL4-associated factor 7  4  1  
rRNA methyltransferase 1, mitochondrial  4  1  
Transcription factor COE4  4  1  
Translation machinery-associated protein 16  4  1  
WD repeat-containing protein 3  4  1  
F-box only protein 25  4  0  
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Target of EGR1 protein 1  4  0  
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